Richard Grossman: Preparing for Shareholder Activism On Your M&A Deal

September 26, 2019 | Activist Updates, Hedge Funds, News
https://dailyalts.com/wp-content/uploads/2019/09/57e0d3404e56ae14ea898579ce203e7c1d22dfe05558784f742879d1_640.jpg

M&A is attractive to activists for its rich returns. How can a company steer its M&A deal past (or with) activist hedge funds?

Richard Grossman, a partner in Skadden’s M&A practice, has advice on tackling activist hedge funds during an M&A transaction.

Firstly, structuring a deal that skirts shareholder approval requirements is no guarantee it will get past activist scrutiny. Grossman cites the example of Occidental’s acquisition of Anadarko Petroleum which technically did not need shareholder approval. Carl Icahn’s campaign nevertheless took a different route for the removal of the company’s directors and alteration of its charter documents.

Act as your activist

A company should take a proactive approach and prepare by “acting as its own activist.” That’s done well by proposing a well-reasoned transaction rationale and evidence of careful and professional consideration by the board. Above all, the transaction should, and be seen to, create value for stakeholders.

However, understand that ongoing communication and advance dialogues with shareholders can be instrumental in heading off potential objections amid a deal.

Plan and prepare for activist hedge funds

Plan well for opposition from an activist. Identify potential criticisms from activist hedge funds, and prepare rebuttals in advance.

It’s important also to recognize the tools of the activist’s trade, in other words, their legal arsenal. These include a proxy battle, litigation, or a “books and records” demand. Also, check for lurking loopholes in the company’s governing documents which the activist hedge fund can exploit.

What are the trends?

During the first half of 2019:

  • 37 companies faced demands from activists for M&A
  • 18 companies faced objections to proposed M&A
  • 13 companies fielded demands for breaking up the business or spin-offs

“As activism has become a widely accepted strategy to generate “alpha,” we expect that activism will continue to have a significant impact on M&A deals,” says Grossman.

The article “Deliberate process” by Richard Grossman appeared in M&A Activism 2019, a report published by Activist Insight.

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Shape

Latest Alternative Investment News

https://dailyalts.com/wp-content/uploads/2023/05/webimage-5e3ef5d0-aee9-4a3e-9d3e-c26109b53529.png
FinTech: Klarna’s All-In Efforts To Achieve Profitability Getting Traction
May 26, 2023     FinTech, News

Swedish fintech company Klarna achieved a significant improvement in its financial performance during the first quarter, as it halved its net loss compared to the same period last year. The…

https://dailyalts.com/wp-content/uploads/2023/05/ai-generated-g831120c83_640.jpg
Alternative Investments/AI: Euclidean Technologies Launches ETF For AI-Selected Value Stocks

Seattle-based investment advisor Euclidean Technologies Management has launched its first exchange-traded fund (ETF), the Euclidean Fundamental Value ETF (ECML US). The actively managed US equity fund utilizes artificial intelligence (AI)…

https://dailyalts.com/wp-content/uploads/2023/05/aditya-siva-6rDbvXzIVpQ-unsplash.jpg
Venture Capital: Matrix Partners Raises $550M For Its Fourth India Fund
May 26, 2023     News, Venture Capital

Matrix Partners India, a venture capital firm focused on investments in India, has announced the closure of its latest fund, securing over $550 million in commitments. This new fund from…

https://dailyalts.com/wp-content/uploads/2023/05/52747633301_b52ecbc442_c.jpg
Artificial Intelligence: AI Helps Researchers Find A Compound To Kill The Drug-Resistant A. baumannii Bacterium

Scientists at MIT and McMaster University have used artificial intelligence (AI) to identify a new antibiotic that can combat drug-resistant infections caused by Acinetobacter baumannii. The bacterium is commonly found…